Annual report pursuant to Section 13 and 15(d)

Acquisition of Patents and Intangibles (Tables)

v3.21.2
Acquisition of Patents and Intangibles (Tables)
12 Months Ended
May 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Activity

The following presents intangible assets activity, inclusive of patents (in thousands):

​

​

​

​

​

​

​

​

    

May 31,

​

​

2021

​

2020

Leronlimab (PRO 140) patent

​

$

3,500

​

$

3,500

ProstaGene, LLC intangible asset acquisition, net of impairment

​

 

2,926

​

​

15,126

Website development costs

​

 

20

​

 

20

Gross carrying value

​

​

6,446

​

​

18,646

Accumulated amortization, net of impairment

​

 

(4,793)

​

 

(5,190)

Total amortizable intangible assets, net

​

$

1,653

​

$

13,456

Schedule of estimated future amortization expense

​

​

​

​

​

Fiscal Year

    

Amount

2022

​

$

669

2023

​

​

384

2024

​

​

85

2025

​

​

85

Thereafter

​

​

430

Total

​

$

1,653

Summary of net purchase price and allocation to the acquired assets

A summary of the net purchase price and allocation to the acquired assets is as follows (in thousands):

​

​

​

​

​

​

ProstaGene, LLC

CytoDyn Inc. equity

​

$

11,558

Acquisition expenses

​

 

741

Release of deferred tax asset

​

 

2,827

Total cost of acquisition

​

$

15,126

Intangible assets

​

$

15,126

Other

​

 

—

Allocation of acquisition costs

​

$

15,126